Germany kicks off EUR2.4bn bioeconomy research programme


Berlin – Germany has launched a research programme aimed at establishing a bio-based economy by 2030. "Our goal is to support the shift in industrial production from oil-based towards bio-based CO2-neutral, sustainable, and competitive processes for generating energy, chemical products and sufficient quantities of high-quality foods and feed" said research state secretary Thomas Rachel in Berlin. According to the 'National BioEconomy Strategy 2030', which kicks-off with a EUR100m fund for Industrial Biotech next year, EUR1.1bn will be invested to boost biomass production while establishing sustainable agricultural methods. EUR792m are earmarked to improve industrial biomass conversion technologies and biorefineries, and EUR504m will be used to push bio-based methods for energy production.
While state secretary Rachel underlined that the research programme is not aimed at favouring certain technologies but intends to find the best way of tackling global challenges such as world hunger or climate change, Holger Zinke (Brain AG), a member of the government's BioEconomy Council said that industrial biotechnology will be the engine of the biobased economy. "In 2007, biotechnological methods were used in 7% of the processes in the chemical industry, today it is 10%. This means the share of biotech methods in the chemical industry doubles every 8 years." According to Zinke, the shift towards bio-based production is happening already and companies such as BASF, Süd-Chemie and Evonik have already increased their R&D spend. Biotech organisations such as DIB and BIO Deutschland, and the head of the Bioeconomy Council, Prof. Reinhard Hüttl welcomed the programme and its priorities. "The main challenge is now to pool the know-how from very different industry sectors and research fields to find the best solutions", said Hüttl, whose 19 experts had presented recommendations for the bioeconomy programme in September. The experts are expected to provide a more detailed list of funding priorities in the different research fields by April 2011. Rachel said the Bioeconomy research agenda is the first of its kind worldwide. EU representatives said in Berlin, the European Commission will present a bioeconomy research agenda within 1 year and aims to implement the topic with 2bn funding in FP8.



The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...



Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...



Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...



German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....



Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight. The 2011 total revenue was...



Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...


Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...



Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...



Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...



Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%


  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%


  • CO.DON3.15 EUR22.1%
  • WILEX3.59 EUR21.3%
  • FORMYCON28.00 EUR21.0%


  • CYTOS1.01 CHF-27.9%
  • BIOTEST79.20 EUR-18.1%
  • THERAMETRICS0.07 CHF-12.5%


  • SANTHERA98.85 CHF2460.9%
  • CYTOS1.01 CHF676.9%
  • WILEX3.59 EUR337.8%


  • MOLOGEN5.07 EUR-54.8%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.41 EUR-28.1%

No liability assumed, Date: 25.04.2015

Current issue

All issues